-
September 02, 2010
AstraZeneca will be celebrating news that its antipsychotic Seroquel XR has been given the European Commission’s seal of approval as an add-on treatment for major depressive episodes in patients with Major Depressive Disorder (MDD).
-
September 02, 2010
UK drugmaker Archimedes Pharma will be corking the champagne after receiving a regulatory green light to market its flagship pain spray PecFent (formerly NasalFent) throughout the European Union.
-
September 02, 2010
Cancer Research UK has started clinical trials of Merck & Co’s MK-0752 in combination with Eli Lilly’s Gemzar in patients with advanced pancreatic cancer.
-
September 02, 2010
Giving GPs responsibility for commissioning alongside service provision is crucial for better integration of health services and thus overall outcomes, a report by The Nuffield Trust has concluded
-
September 02, 2010
UK drug giant GlaxoSmithKline has confirmed that prescribing information regarding its cervical cancer jab Cervarix has been updated to show that it offers broader protection against the disease.
-
August 31, 2010
Public service union UNISON is taking the government to court over its failure to consult properly on the proposals for change laid out in the National Health Service white paper.
-
August 31, 2010
Celgene’s Thalidomide and Janssen-Cilag’s Velcade have been recommended as options to treat patients with multiple myeloma on the National Health Service by its cost regulator.
-
August 31, 2010
The rate of oesophageal cancer in men in the UK has rocketed more than 50% over the last 25 years, according to new data from the charity Cancer Research UK.
-
August 26, 2010
Professor Sir Michael Rawlins, chairman of NICE, has suggested that instead of developing complex schemes such as rebates to increase patient access to their innovative but expensive new treatments, drugmakers could simply offer the NHS deeper initial discounts.
-
August 26, 2010
The National Institute for Health and Clinical Excellence has barred Novartis’ Glivec from the National Health Service in England and Wales as an option for stomach cancer recurrence.